Studies have further confirmed that CDK4/6 selective inhibitors and estrogen receptor (ER) antagonists exhibit significant synergistic effects in inhibiting the proliferation of ER-positive breast cancer cells (3). Here, ESR1 is linked to breast carcinoma.